J Immunother 2021 Apr 28. Epub 2021 Apr 28.
Jules Bordet Institute, Brussels University Hospital Antwerp, Edegem, Belgium Drug Development Department (DITEP), Gustave Roussy Institute, Villejuif, France Department of Hematology-Oncology, Indiana University Simon Comprehensive Cancer Center Eli Lilly and Company Indiana University School of Medicine, Indianapolis, IN Ghent University Hospital, Ghent, Belgium Eli Lilly and Company, New York, NY Eli Lilly and Company, Stockholm, Sweden Eli Lilly and Company, Surrey, UK Sarah Cannon Research Institute Tennessee Oncology, Nashville, TN.
LY3381916 is an orally available, highly selective, potent inhibitor of indoleamine 2,3-dioxygenase 1. This study explored the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of LY3381916 monotherapy and in combination with a programmed death-ligand 1 (PD-L1) inhibitor (LY3300054) in patients with advanced solid tumors. During dose escalation, patients received escalating doses of LY3381916 at 60-600 mg once daily (qd) and 240 mg twice daily in monotherapy (n=21) and in combination with PD-L1 inhibitor at 700 mg every 2 weeks (n=21). Read More